Delta Investment Management LLC Acquires 5,284 Shares of Johnson & Johnson $JNJ

Delta Investment Management LLC increased its holdings in Johnson & Johnson (NYSE:JNJ) by 63.0% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 13,674 shares of the company’s stock after acquiring an additional 5,284 shares during the period. Delta Investment Management LLC’s holdings in Johnson & Johnson were worth $2,535,000 at the end of the most recent quarter.

A number of other hedge funds have also added to or reduced their stakes in the stock. Heritage Oak Wealth Advisors LLC lifted its holdings in shares of Johnson & Johnson by 3.5% in the third quarter. Heritage Oak Wealth Advisors LLC now owns 1,639 shares of the company’s stock valued at $304,000 after purchasing an additional 55 shares in the last quarter. Lifestyle Asset Management Inc. raised its position in Johnson & Johnson by 3.4% in the 3rd quarter. Lifestyle Asset Management Inc. now owns 1,683 shares of the company’s stock valued at $312,000 after buying an additional 56 shares during the last quarter. Wynn Capital LLC lifted its stake in Johnson & Johnson by 0.4% during the 3rd quarter. Wynn Capital LLC now owns 15,930 shares of the company’s stock valued at $2,954,000 after acquiring an additional 57 shares in the last quarter. Defined Financial Planning LLC boosted its holdings in Johnson & Johnson by 3.0% during the 3rd quarter. Defined Financial Planning LLC now owns 1,926 shares of the company’s stock worth $365,000 after acquiring an additional 57 shares during the last quarter. Finally, Trail Ridge Investment Advisors LLC grew its stake in shares of Johnson & Johnson by 0.9% in the 3rd quarter. Trail Ridge Investment Advisors LLC now owns 6,375 shares of the company’s stock worth $1,182,000 after acquiring an additional 57 shares in the last quarter. Institutional investors and hedge funds own 69.55% of the company’s stock.

Wall Street Analyst Weigh In

JNJ has been the topic of several analyst reports. Argus set a $210.00 price target on shares of Johnson & Johnson in a report on Wednesday, October 15th. Loop Capital set a $190.00 target price on Johnson & Johnson in a research note on Wednesday, October 22nd. Raymond James Financial increased their price target on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research report on Wednesday, October 15th. Daiwa Capital Markets raised Johnson & Johnson from a “neutral” rating to an “outperform” rating and set a $203.00 price objective on the stock in a research report on Monday, October 20th. Finally, Scotiabank assumed coverage on Johnson & Johnson in a research report on Thursday, November 13th. They set a “sector outperform” rating and a $230.00 target price for the company. Four equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating and nine have assigned a Hold rating to the company’s stock. According to data from MarketBeat, Johnson & Johnson currently has a consensus rating of “Moderate Buy” and a consensus target price of $211.25.

Johnson & Johnson Stock Performance

NYSE:JNJ opened at $207.26 on Friday. The company has a market capitalization of $499.35 billion, a P/E ratio of 20.01, a P/E/G ratio of 2.13 and a beta of 0.34. The business has a fifty day simple moving average of $201.17 and a two-hundred day simple moving average of $182.85. The company has a debt-to-equity ratio of 0.50, a current ratio of 1.07 and a quick ratio of 0.80. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $215.18.

Johnson & Johnson (NYSE:JNJ) last issued its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 EPS for the quarter. Johnson & Johnson had a return on equity of 32.73% and a net margin of 27.26%.The firm had revenue of $24.02 billion for the quarter. On average, analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Tuesday, February 24th will be paid a $1.30 dividend. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 annualized dividend and a dividend yield of 2.5%. Johnson & Johnson’s dividend payout ratio (DPR) is presently 50.19%.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.